Status: Recruiting
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Raymond ChungUpdated: Sep 23, 2025Locations: 2
Eligibility criteria
Willing and able to provide informed consent [+11]
alpha-1-antitrypsin (A1AT) deficiency, Wilson disease, hemochromatosis, iron ove... [+23]